Rhythm Pharma's Q1 2026: $60M Revenue, New Approval, Expansion

Rhythm Pharmaceuticals Q1 2026 earnings soared to $60M, up from $57M last quarter, driven by IMCIVREEs success in rare obesity conditions. The FDAs recent approval for acquired hypothalamic obesity, affecting 10K patients in the US and Europe, boosted revenue. The US launch gained momentum with 150 patient start forms, and Europes marketing authorization paves the way for 2027 launches. Physicians appreciate the broad label, and real-world data from French programs builds excitement. Japans fast-track approval is expected by year-end 2026. Despite increased expenses, Rhythm has $341M in cash for at least 24 months. Looking ahead, phase three trials for next-gen therapies and Prader-Willi data expansion promise more growth in the ultra-rare space. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ab97ef7b895b704d